IN THE CLAIMS

1. (currently amended) An oral controlled release pharmaceutical composition having a controlled release core, said core comprising: a) a therapeutically effective amount of at least one pharmaceutically active ingredient; b) an optional surface active agent; c) an optional pharmaceutically acceptable alkaline agent; and d) at least one water soluble binder and at least one water insoluble binder; wherein the controlled release is achieved by way of the water soluble and water insoluble binders, and wherein the pharmaceutically active ingredient is selected from anti-diabetics, HMG-CoA reductase inhibitors or mixtures thereof.

2. (original) The composition of claim 1, further comprising a single layer of coating on said core, said coating comprising an enteric coating agent.

3. (canceled)

4. (canceled)

5. (canceled)

6. (original) The composition of claim 1, wherein the water-insoluble binder is a polymethacrylic acid copolymer.

7. (original) The composition of claim 1 wherein the enteric coating comprises a component selected from cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellu- lose, or co-polymerized methacrylic acid/methacrylic acid methyl esters.

8. (canceled)

9. (canceled)

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20. (currently amended) A oral controlled release pharmaceutical composition having a controlled release core, said core consisting essentially of: a therapeutically effective amount of a pharmaceutically active ingredient, an optional surface active agent, an optional pharmaceutically acceptable alkaline agent, at least one water soluble binder and at least one water insoluble binder; wherein said controlled release is achieved through the use of said water soluble and water insoluble binders and wherein said pharmaceutically active ingredient is selected from anti-diabetics, HMG-CoA reductase inhibitors or mixtures thereof.

21. (currently amended) A method for manipulating bioavailability of a pharmaceutical dosage formulation comprising a core having powdered components, a

pharmaceutically active ingredient and a coating, said pharmaceutically active ingredient being selected from anti-diabetics, HMG-CoA reductase inhibitors or mixtures thereof said method comprising the step of providing at least one water-insoluble binder and at least one water soluble binder in the core to control cohesiveness of powdered core components upon disintegration of the core.

22. (original) The method of claim 21, wherein the water-insoluble binder is a polymethacrylic acid copolymer.

23. (new) The composition of claim 1 wherein said anti-diabetic is a sulfonylurea.

24. (new) The composition of claim 23 wherein said sulfonylurea is glipizide.

25. (new) The composition of claim 20 wherein said anti-diabetic is a sulfonylurea.

26. (new) The composition of claim 25 wherein said sulfonylurea is glipizide.

27. (new) The method of claim 21 wherein said anti-diabetic is a sulfonylurea.

28. (new) The method of claim 27 wherein said sulfonylurea is glipizide.

29. (new) The composition of claim 1 wherein said HMG-CoA reductase inhibitor is lovastatin.

30. (new) The composition of claim 20 wherein said HMG-CoA reductase inhibitor is lovastatin.

31. (new) The method of claim 21 wherein said HMG-CoA reductase inhibitor is lovastatin.

32. (new) The composition of claim 1 wherein said water soluble and water insoluble binders comprise from 0 to about 10 wt% of the composition.

33. (new) The composition of claim 1 wherein said active ingredient comprises from about 5 to about 70 wt% of the composition.

34. (new) The composition of claim 20 wherein said water soluble and water insoluble binders comprise from 0 to about 10 wt% of the composition.

35. (new) The composition of claim 20 wherein said active ingredient comprises from about 5 to about 70 wt% of the composition.

36. (new) The method of claim 21 wherein said water soluble and water insoluble binders comprise from 0 to about 10 wt% of the composition.

37. (new) The method of claim 21 wherein said active ingredient comprises from about 5 to about 70 wt% of the composition.